Hydrocodone-Doxapram Combination
Pain management with reduced risk of respiratory depression and abuse deterrence
Pre-clinicalActive
Key Facts
Indication
Pain management with reduced risk of respiratory depression and abuse deterrence
Phase
Pre-clinical
Status
Active
Company
About Quivive Pharma
Quivive Pharma is a private, preclinical-stage biotech addressing the opioid overdose epidemic through a novel drug delivery and safety platform. Its lead strategy involves repurposing Doxapram, an FDA-approved drug, as a functional antagonist to counteract opioid-induced respiratory depression—the primary cause of overdose deaths—while preserving analgesia. The company aims to develop abuse-deterrent opioid formulations that close a significant safety gap left by current products and address the major gateway to opioid addiction.
View full company profile